A Tiny Biotech Startup Wages War Against AIDS

One of the most promising attacks on the dread disease was produced far from the meccas of biotechnology The message transmitted from the fourth International Conference on AIDS in Stockholm this June was bleak. Seven thousand of the world’s leading scientists had gathered to hear more than 3,100 presentations and to discuss what has been learned about the virus. “Not enough” was the answer. An estimated five million to 10 million people have been infected with the HIV virus,

| 9 min read

Register for free to listen to this article
Listen with Speechify
0:00
9:00
Share

The message transmitted from the fourth International Conference on AIDS in Stockholm this June was bleak. Seven thousand of the world’s leading scientists had gathered to hear more than 3,100 presentations and to discuss what has been learned about the virus. “Not enough” was the answer. An estimated five million to 10 million people have been infected with the HIV virus, one million of these United States citizens. And, though scientific knowledge and understanding of the virus is expanding, little progress has been made over the past year toward a vaccine or effective treatment. But amidst the pessimism and gloom, a small poster display struck a rare, optimistic note. It showed clinical test results of a proposed therapeutic that appears to be effective in slowing the ravages of the wasting disease. Each day, more than a dozen clerks rustle through stacks of patient records as they photocopy, compile, and review ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

  • David Graham

    This person does not yet have a bio.

Published In

Share
TS Digest January 2025
January 2025, Issue 1

Why Do Some People Get Drunk Faster Than Others?

Genetics and tolerance shake up how alcohol affects each person, creating a unique cocktail of experiences.

View this Issue
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo
New Frontiers in Vaccine Development

New Frontiers in Vaccine Development

Sino
New Approaches for Decoding Cancer at the Single-Cell Level

New Approaches for Decoding Cancer at the Single-Cell Level

Biotium logo
Learn How 3D Cell Cultures Advance Tissue Regeneration

Organoids as a Tool for Tissue Regeneration Research 

Acro 

Products

Artificial Inc. Logo

Artificial Inc. proof-of-concept data demonstrates platform capabilities with NVIDIA’s BioNeMo

Sapient Logo

Sapient Partners with Alamar Biosciences to Extend Targeted Proteomics Services Using NULISA™ Assays for Cytokines, Chemokines, and Inflammatory Mediators

Bio-Rad Logo

Bio-Rad Extends Range of Vericheck ddPCR Empty-Full Capsid Kits to Optimize AAV Vector Characterization

Scientist holding a blood sample tube labeled Mycoplasma test in front of many other tubes containing patient samples

Accelerating Mycoplasma Testing for Targeted Therapy Development